-DOCSTART- -X- O
T-cell-mediated -X- _ O
immunotherapy -X- _ O
of -X- _ O
hematological -X- _ O
malignancies -X- _ O
requires -X- _ O
selection -X- _ O
of -X- _ O
targeted -X- _ O
tumor-associated -X- _ O
antigens -X- _ O
and -X- _ O
T-cell -X- _ O
epitopes -X- _ O
contained -X- _ O
in -X- _ O
these -X- _ O
tumor -X- _ O
proteins. -X- _ O
Epidermal -X- _ B-Intervention
growth -X- _ I-Intervention
factor -X- _ I-Intervention
receptor -X- _ I-Intervention
pathway -X- _ I-Intervention
substrate -X- _ I-Intervention
8 -X- _ I-Intervention
( -X- _ I-Intervention
EPS8 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
whose -X- _ O
function -X- _ O
is -X- _ O
pivotal -X- _ O
for -X- _ O
tumor -X- _ O
proliferation -X- _ O
, -X- _ O
progression -X- _ O
and -X- _ O
metastasis -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
found -X- _ O
to -X- _ O
be -X- _ O
overexpressed -X- _ O
in -X- _ O
most -X- _ O
human -X- _ O
tumor -X- _ O
types -X- _ O
, -X- _ O
while -X- _ O
its -X- _ O
expression -X- _ O
in -X- _ O
normal -X- _ O
tissue -X- _ O
is -X- _ O
low. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
identify -X- _ O
human -X- _ B-Intervention
leukemia -X- _ I-Intervention
antigen -X- _ I-Intervention
( -X- _ I-Intervention
HLA -X- _ I-Intervention
) -X- _ I-Intervention
-A*0201-restricted -X- _ I-Intervention
epitopes -X- _ I-Intervention
of -X- _ I-Intervention
EPS8 -X- _ I-Intervention
by -X- _ O
using -X- _ O
a -X- _ O
reverse -X- _ O
immunology -X- _ O
approach. -X- _ O
To -X- _ O
achieve -X- _ O
this -X- _ O
, -X- _ O
computer -X- _ O
algorithms -X- _ O
were -X- _ O
used -X- _ O
to -X- _ O
predict -X- _ O
HLA-A*0201 -X- _ O
molecular -X- _ O
binding -X- _ O
, -X- _ O
proteasome -X- _ O
cleavage -X- _ O
patterns -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
translocation -X- _ O
of -X- _ O
transporters -X- _ O
associated -X- _ O
with -X- _ O
antigen -X- _ O
processing. -X- _ O
Candidate -X- _ O
peptides -X- _ O
were -X- _ O
experimentally -X- _ O
validated -X- _ O
by -X- _ O
T2 -X- _ O
binding -X- _ O
affinity -X- _ O
assay -X- _ O
and -X- _ O
brefeldin-A -X- _ O
decay -X- _ O
assay. -X- _ O
The -X- _ O
functional -X- _ O
avidity -X- _ O
of -X- _ O
peptide-specific -X- _ O
cytotoxic -X- _ O
T -X- _ O
lymphocytes -X- _ O
( -X- _ O
CTLs -X- _ O
) -X- _ O
induced -X- _ O
from -X- _ O
peripheral -X- _ O
blood -X- _ O
mononuclear -X- _ O
cells -X- _ O
of -X- _ O
healthy -X- _ B-Patient
volunteers -X- _ I-Patient
were -X- _ O
evaluated -X- _ O
by -X- _ O
using -X- _ O
an -X- _ O
enzyme-linked -X- _ O
immunosorbent -X- _ O
spot -X- _ O
assay -X- _ O
and -X- _ O
a -X- _ O
cytotoxicity -X- _ O
assay. -X- _ O
Four -X- _ B-Outcome
peptides -X- _ I-Outcome
, -X- _ I-Outcome
designated -X- _ I-Outcome
as -X- _ I-Outcome
P455 -X- _ I-Outcome
, -X- _ I-Outcome
P92 -X- _ I-Outcome
, -X- _ I-Outcome
P276 -X- _ I-Outcome
and -X- _ I-Outcome
P360 -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
high -X- _ I-Outcome
affinity -X- _ I-Outcome
and -X- _ I-Outcome
stability -X- _ I-Outcome
of -X- _ I-Outcome
binding -X- _ I-Outcome
towards -X- _ I-Outcome
the -X- _ I-Outcome
HLA-A*0201 -X- _ I-Outcome
molecule -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
specific -X- _ I-Outcome
CTLs -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
them -X- _ I-Outcome
significantly -X- _ I-Outcome
responded -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
corresponding -X- _ I-Outcome
peptides -X- _ I-Outcome
and -X- _ I-Outcome
secreted -X- _ I-Outcome
IFN-Î³. -X- _ I-Outcome
At -X- _ I-Outcome
the -X- _ I-Outcome
same -X- _ I-Outcome
time -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
CTLs -X- _ I-Outcome
were -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
specifically -X- _ I-Outcome
lyse -X- _ I-Outcome
EPS8-expressing -X- _ I-Outcome
cell -X- _ I-Outcome
lines -X- _ I-Outcome
in -X- _ I-Outcome
an -X- _ I-Outcome
HLA-A*0201-restricted -X- _ I-Outcome
manner. -X- _ I-Outcome
The -X- _ O
present -X- _ O
study -X- _ O
demon-strated -X- _ O
that -X- _ O
P455 -X- _ O
, -X- _ O
P92 -X- _ O
, -X- _ O
P276 -X- _ O
and -X- _ O
P360 -X- _ O
were -X- _ O
CTL -X- _ O
epitopes -X- _ O
of -X- _ O
EPS8 -X- _ O
, -X- _ O
and -X- _ O
were -X- _ O
able -X- _ O
to -X- _ O
be -X- _ O
used -X- _ O
for -X- _ O
epitope-defined -X- _ O
adoptive -X- _ O
T-cell -X- _ O
transfer -X- _ O
and -X- _ O
multi-epitope-based -X- _ O
vaccine -X- _ O
design -X- _ O
. -X- _ O

